More on RYTM
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $102.10 |
|
|||
| Open | $104.64 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $109.53 | ||||
| Day Low | $102.75 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 385,461 | ||||
- JPMorgan Starts Rhythm Pharmaceuticals (RYTM) at Overweight
- Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
- Rhythm Pharmaceuticals (RYTM) Reiterated at Market Outperform by Citizens
- Rhythm Pharmaceuticals TRANSCEND trial results published in NEJM
- Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity
- Rhythm Pharmaceuticals (RYTM) PT Raised to $141 at RBC Capital
- Form 4 RHYTHM PHARMACEUTICALS, For: Jul 01 Filed by: Garfield Alastair
- This biotech stock is on TD Cowen's best smidcap ideas list
- Form 4 RHYTHM PHARMACEUTICALS, For: Jun 23 Filed by: JEAN CHRISTOPHE
- Form 4 RHYTHM PHARMACEUTICALS, For: Jun 23 Filed by: MCGIRR DAVID W J
Entities mentioned with RYTM
- FDA | View Related Stories »
- PDUFA | View Related Stories »
- ARK | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Maynard Um | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- Needham & Company | View Related Stories »
- Show More...
